MBX Biosciences Inc (MBX) FinancialsMBXFinancialMBX Biosciences Inc

Evaluating the bottom line, MBX Biosciences, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -33.17%, provide a clear picture of how effectively MBX converts its operational activities into shareholder value.

In the context of the broader market, MBX competes directly with industry leaders such as BEAM and CLDX. With a market capitalization of $3.20B, it holds a significant position in the sector. When comparing efficiency, MBX's gross margin of N/A stands against BEAM's 100.00% and CLDX's 100.00%. Such benchmarking helps identify whether MBX Biosciences, Inc. is trading at a premium or discount relative to its financial performance.

MBX reported a GAAP EPS of -$0.78 for Q2 2026, and the net loss increased significantly from $19.4 million in Q2 2025 to $37.1 million in Q2 2026, reflecting ongoing financial challenges.